What We Believe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It is not a matter of editorial opinion to say these words: Black Lives Matter.

The existence of systemic racism, social inequality, and health disparities is indisputable, and not a matter of bias or opinion. This is grounded in science and data.

Cancer does not discriminate. Our social infrastructure does.

The Cancer Letter strives to give you unbiased, balanced coverage grounded in standards of evidence-based medicine, the principles of peer review, disclosures, health equity, and social justice.

Our coverage since 1973 has adhered to this mission. But all of us must do more.

Diversity is fundamental to fair and balanced coverage, and to achieving health equity. As a news publication, we must amplify the voices of those who have been historically marginalized. This requires an ongoing, concerted effort in a world where the people who hold the keys to power are disproportionately white and male.

NCI should be commended for emphasizing Community Outreach and Engagement as a key criterion for the designation of cancer centers. However, as a logical next step, we must also examine diversity at the cancer centers.

Of the 71 directors of NCI-Designated Cancer Centers, the vast majority are white and male. One is African American. Nine are women.

What does the leadership pipeline look like? We don’t know. No robust data exist on the diversity among directors and deputy directors of NCI-designated cancer centers. These data should be generated, and made publicly available.

All of us—scientists, physicians, and journalists—have a role to play in bringing forward diverse viewpoints. It’s fair, it’s equitable, and it’s essential to good science.

“In my experience, our endemic institutional racism is, and has always been, a public health issue,” Robert Winn writes. “In fact—as a result of the COVID-19 disaster—we are all now finally recognizing that racism is a contributing factor to chronic diseases, including cancer.”

Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login